Borzomed 3.5 mg contains Bortezomib, a first-in-class proteasome inhibitor that has significantly advanced the treatment of multiple myeloma and certain lymphomas.
It is administered as a subcutaneous injection or intravenous infusion, typically in cycles, and has become a cornerstone therapy by helping control disease progression and prolonging survival.

Mechanism of Action

Bortezomib targets the 26S proteasome, a cellular complex responsible for breaking down unwanted or damaged proteins.

• In multiple myeloma and some lymphoma cells, rapid protein turnover is essential for their uncontrolled growth.

• By inhibiting the proteasome, bortezomib causes a buildup of these proteins, disrupting multiple signaling pathways.

• This stress leads to cell cycle arrest and programmed cell death (apoptosis) of cancer cells.

  Uses / Indications

  Borzomed (bortezomib) is used in the treatment of:

  • Multiple myeloma (MM):

    • As first-line therapy in newly diagnosed patients (often combined with other drugs like dexamethasone, lenalidomide, or cyclophosphamide).

    • In relapsed or refractory disease to regain control of progression.

  • Mantle cell lymphoma (MCL):

    • Particularly in patients who have received at least one prior therapy.

      Adverse Effects

      Because it interferes with core cellular functions, bortezomib can affect both cancerous and healthy fast-dividing cells.

      Common side effects include:

      • Peripheral neuropathy (numbness, tingling, burning in hands or feet) — one of the most important side effects, which may improve after dose adjustments or treatment completion.

      • Fatigue, mild nausea, diarrhoea or constipation.

      • Low blood counts (white cells, red cells, platelets), increasing risks of infection, anaemia, and bleeding.

      • Mild rash or injection site reactions.